Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review

易普利姆玛 医学 无容量 中毒性表皮坏死松解 黑色素瘤 皮疹 不利影响 肿瘤科 内科学 皮肤病科 联合疗法 癌症 免疫疗法 癌症研究
作者
Ian T. Logan,Saman Zaman,Lama Hussein,Conal M. Perrett
出处
期刊:Journal of Immunotherapy [Lippincott Williams & Wilkins]
卷期号:43 (3): 89-92 被引量:38
标识
DOI:10.1097/cji.0000000000000302
摘要

Ipilimumab and nivolumab are immune checkpoint inhibitors used in the treatment of metastatic melanoma. The authors report the case of a 62-year-old white male individual with metastatic choroidal melanoma who had commenced adjuvant systemic treatment with combination checkpoint inhibitor therapy of intravenous ipilimumab (anti-cytotoxic T-lymphocyte antigen-4) and nivolumab (anti-programmed cell death-1) at 3-week cycle intervals. On day 4 after the second cycle, he developed an acute widespread rash. On examination there was confluent erythema with bullae and epidermal loss over 60% of the body surface area, with severe oral mucosal ulceration. A clinical diagnosis of toxic epidermal necrolysis (TEN) was made and he was transferred to the intensive care unit. Despite active treatment, he deteriorated systemically and died from multiorgan failure. This is the first reported case of TEN associated with nivolumab and ipilimumab dual therapy for metastatic uveal melanoma. Monotherapy improves survival in metastatic melanoma, but dual therapy has shown a greater mortality benefit at 3 years. Although the literature demonstrates case reports of Stevens-Johnson syndrome and TEN in association with nivolumab, ipilimumab has generally been regarded as a “safe” treatment with regard to severe cutaneous adverse reactions. With the increased use of immunotherapies, it is important to plan the management and early recognition of drug-related skin toxicity. This is of greatest concern during treatment initiation and with the higher risk associated with combination therapy. Reporting of adverse events and infrequently encountered complications with systemic biologic treatments will augment pharmacovigilance and improve the stratification of patients to treatments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
Tsuzuri应助科研通管家采纳,获得10
刚刚
1秒前
ding应助科研通管家采纳,获得10
1秒前
所所应助科研通管家采纳,获得10
1秒前
zhangqin完成签到,获得积分10
2秒前
2秒前
3秒前
脑洞疼应助zzzzzze采纳,获得30
3秒前
4秒前
4秒前
4秒前
小杨发布了新的文献求助10
5秒前
samifranco完成签到,获得积分20
5秒前
邢绿凝发布了新的文献求助10
5秒前
6秒前
桐桐应助Ari_Kun采纳,获得10
6秒前
852应助小璐璐呀采纳,获得10
7秒前
7秒前
秀儿发布了新的文献求助10
8秒前
8秒前
10秒前
善学以致用应助小杨采纳,获得10
11秒前
gnil给gnil的求助进行了留言
14秒前
研友_ZeqAxZ完成签到,获得积分10
15秒前
18岁187腹肌纯情男高完成签到,获得积分10
15秒前
白桃战士完成签到,获得积分10
15秒前
sns八丘完成签到,获得积分10
16秒前
cwn完成签到 ,获得积分10
17秒前
17秒前
18秒前
peekaboo发布了新的文献求助10
18秒前
科研通AI5应助hejilianglove采纳,获得10
18秒前
怕黑的凡灵完成签到 ,获得积分10
19秒前
19秒前
21秒前
喝牛奶de猪完成签到,获得积分10
21秒前
爆米花应助zzz采纳,获得10
22秒前
赵保钢完成签到,获得积分10
23秒前
高分求助中
Les Mantodea de Guyane Insecta, Polyneoptera 2500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
Technologies supporting mass customization of apparel: A pilot project 450
A China diary: Peking 400
Brain and Heart The Triumphs and Struggles of a Pediatric Neurosurgeon 400
Cybersecurity Blueprint – Transitioning to Tech 400
Mixing the elements of mass customisation 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3784104
求助须知:如何正确求助?哪些是违规求助? 3329207
关于积分的说明 10240907
捐赠科研通 3044742
什么是DOI,文献DOI怎么找? 1671248
邀请新用户注册赠送积分活动 800203
科研通“疑难数据库(出版商)”最低求助积分说明 759241